RE:Emerging markets
Eylea and Lucentis are both FDA approved for the treatment of Diabetic Retinopathy. Regeneron and Genentech both received expansions on FDA approval for Eylea and Lucentis to include the treatment of diabetic retinopathy in people with macular edema. They received the expanded approval in February (Genentech) and March (Regeneron) of this year. Based on contracts announced over the past year it appears that revenues for CARA will be better (year over last), and based on continued contract wins it seems that revenues will increase even more this year. Our contract with Regeneron was huge... not just because they are a major US pharma but because they are co-marketing Eylea with Bayer. jmo. From what I've gathered, Regeneron has the U.S. rights and Bayer has the rights to everywhere else. It may be the same marketing arrangement for Genentech and Novartis. Baywall, you mentioned that Bayer is Regeneron's parent company... As far as I know, Bayer doesn't own Regeneron... they co-developed and are now co-marketing Eylea with them.